Technology | December 09, 2014

Volpara Solutions Launches VolparaAnalytics 1.2 at RSNA

Next generation quality assurance tool delivers expanded breast imaging metrics to provide critical insight for breast imaging workflow

Mammography systems, women's health, RSNA 2014, Volpara, breast density

Image courtesy of Volpara Solutions

December 9, 2014 — Volpara Solutions launched VolparaAnalytics version 1.2 at RSNA 2014. Volpara Solutions showcased the latest version of VolparaAnalytics and the rest of its suite of quantitative breast imaging tools, including VolparaDensity and VolparaDoseRT, which enable personalized measurements of volumetric density, patient-specific dose, breast compression and other factors designed to provide insight for breast imaging quality and workflow.

VolparaAnalytics, a centralized dashboard that presents key mammography metrics, works by automatically collating data from digital mammography and tomosynthesis units to enable cross-comparison of patient populations, mammography systems and operator performance. VolparaAnalytics is in use supporting quality assurance at breast imaging centers around the globe by monitoring critical elements of the breast imaging process and generating key metrics to help breast imaging centers identify and address potential issues early.

The new version of VolparaAnalytics, which will be available in early 2015, features an enhanced user interface and reporting tools, and delivers expanded breast imaging metrics to users including additional quality metrics, new temporal analysis tools, additional tools to analyse patient positioning and patient-dose and time between study acquisitions.

Volpara Solutions was recently recognized with the 2014 Technology Innovation Leadership Award in Breast Imaging from Frost & Sullivan based on independent analysis of the company’s technology excellence and visionary innovation. 

“One key new feature of the latest version of VolparaAnalytics is temporal analysis reporting, which allows users to view key breast imaging metrics such as compression force, applied pressure and mean glandular dose results over time to quickly identify inconsistencies that might have developed,” said Ralph Highnam, PhD., Volpara Solutions CEO and Chief Scientist.  “By providing objective volumetric context, this provides actionable insight to help breast centers improve patient care and productivity.”

VolparaAnalytics runs on top of VolparaDensity, a software tool in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images and to determine which women would benefit from additional screening.  Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR (American College of Radiology) breast density categories.  To date, more than 4-million women have had their breast density analyzed using VolparaDensity. VolparaDoseRT provides a standardized measurement of patient-specific dose with consistent dose results across mammography systems from different manufacturers.

For more information: www.volparasolutions.com

 

Related Content

Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.
Feature | Breast Imaging | February 03, 2020 | By Barbara Smith
Women in the United States have a 1 in 8 (or about 13 percent) lifetime risk of being diagnosed with breast cancer du
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Sponsored Content | Videos | Mammography | January 24, 2020
Imaging Technology News Contributing Editor Greg Freiherr interviewed...
Virtual reality during chemotherapy has been shown to improve breast cancer patients’ quality of life during the most stressful treatments
News | Virtual and Augmented Reality | January 21, 2020
January 21, 2020 — Virtual reality during chemotherapy has been shown to improve...